Corvus' early-phase atopic dermatitis data prompt stock rally
Corvus Pharmaceuticals reported new Phase 1 data in atopic dermatitis that sent its stock price $CRVS up by as much as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
